Profile data is unavailable for this security.
About the company
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.
- Revenue in USD (TTM)0.00
- Net income in USD-1.67m
- Incorporated1992
- Employees26.00
- LocationOncotelic Therapeutics Inc29397 Agoura Road Suite 107AGOURA HILLS 91301United StatesUSA
- Phone+1 (650) 635-7000
- Fax+1 (650) 635-7001
- Websitehttps://www.oncotelic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.97m | 13.00 | -- | 0.5644 | -- | 36.21 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 19.52m | 12.00 | -- | -- | -- | 150.12 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 19.54m | 2.00 | -- | 2.48 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 19.89m | 4.00 | -- | 345.16 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 19.92m | 6.00 | -- | -- | -- | 56.85 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Vistagen Therapeutics Inc | 736.00k | -62.24m | 20.03m | 59.00 | -- | 0.2964 | -- | 27.22 | -1.91 | -1.91 | 0.0227 | 1.71 | 0.008 | -- | -- | 13,142.86 | -67.86 | -55.19 | -76.71 | -59.56 | -- | -- | -8,455.98 | -5,842.62 | -- | -- | 0.0098 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.52m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 20.75m | 26.00 | -- | 2.28 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.36m | 18.00 | -- | 1.50 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 21.57m | 7.00 | -- | 2.45 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.78m | 7.00 | -- | 0.7632 | -- | 1.39 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 21.84m | 13.00 | -- | -- | -- | 2.57 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 21.87m | 34.00 | -- | 2.69 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 22.08m | 1.00 | -- | 0.7388 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| Aspira Women's Health Inc | 9.34m | -10.80m | 22.67m | 66.00 | -- | -- | -- | 2.43 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Regentis Biomaterials Ltd | 0.00 | -5.20m | 22.73m | -- | -- | -- | -- | -- | -1.00 | -1.00 | 0.00 | -1.87 | 0.00 | -- | -- | -- | -1,548.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.60 | -- | -- | -- |
